Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Cli6.5
Clindamycin (topisch) – Forschung
Überwiegend Mechanismus / Beobachtung
9 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Clindamycin (topisch) sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2010–2026 mit einer typischen Studiengröße von 22,645 Teilnehmenden.
Basierend auf 9 Studien · 5 Meta-Analysen · 122,425 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Nach Outcome
Skin healthSubstantial reduction in inflammatory lesions when combined with a retinoid or benzoyl peroxide, and the best topical option for moderate-to-severe acne in that pairing. Slower than benzoyl peroxide for the first month, and of little measured benefit on lesion counts alone. · 4-12 weeks
Überwiegend Mechanismus / Beobachtung6 Studien
Muscle strength & power
Zu wenige bewertete Studien1 Studie
Safety profile
Zu wenige bewertete Studien1 Studie
Aktives Forschungsgebiet
6 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
201020182026
1Meta-Analysen=22,645 · very large study2026
Einfach gesagt: Compared with placebo, only dapsone 5% and erythromycin 2% significantly reduced inflammatory lesion counts. … However, no treatment showed a significant improvement in total lesion counts compared to placebo.
Not stated in the abstract · Clin Drug Investig (2026)
32 studies comprising 34 randomised controlled trials, 22,645 patients, searched to October 2025.
⚠️ CLINDAMYCIN WAS NOT AMONG THE AGENTS that significantly reduced inflammatory lesion counts against placebo. Only dapsone 5% and erythromycin 2% were.
⚠️ Nor was it among those reducing non-inflammatory lesions: azithromycin 2%, erythromycin 2%, metronidazole 2% and minocycline 4% were.
2Meta-AnalyseCited 7×n=33,472 · very large study2025
Einfach gesagt: For non-inflammatory acne, the addition of clindamycin in topical regimens is unnecessary and should be avoided.
Not stated in the abstract · J Eur Acad Dermatol Venereol (2025)
35 randomised clinical trials, 33,472 participants, nine topical agents, minimum 12 weeks of treatment.
Adapalene-BPO, clindamycin-BPO and clindamycin-tretinoin produced the greatest reductions in non-inflammatory, inflammatory and total lesion counts against placebo.
⚠️ But clindamycin-tretinoin did NOT significantly outperform tretinoin alone (RoM 1.13, 95% CI 0.94 to 1.36) and clindamycin-BPO did NOT significantly outperform BPO alone (RoM 1.15, 95% CI 0.98 to 1.36) for non-inflammatory lesions.
3Systematische ÜbersichtCited 316×2024
Einfach gesagt: Strong recommendations are made for benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline.
Reynolds RV, et al. · J Am Acad Dermatol (2024)
American Academy of Dermatology guideline built on a systematic review with GRADE assessment: 18 evidence-based recommendations and 5 good practice statements.
Topical antibiotics carry a STRONG recommendation, alongside benzoyl peroxide, topical retinoids and oral doxycycline.
Oral isotretinoin is strongly recommended for acne that is severe, causes psychosocial burden or scarring, or fails standard therapy.
4Systematische ÜbersichtCited 6×n=40,910 · very large study2024
Einfach gesagt: The six reviews involved 40,910 people with acne from 275 trials and 1316 people with acne scars from 37 trials.
Not stated in the abstract · Cochrane Database Syst Rev (2024)
A Cochrane OVERVIEW of systematic reviews rather than of trials, searched to 2 December 2021, excluding reviews at high risk of bias using ROBIS.
⚠️ Of 733 records retrieved, only SIX reviews met the inclusion criteria at low risk of bias. That is the headline about this literature.
Those six covered 40,910 people with acne from 275 trials, plus 1,316 with acne scars from 37 trials, aged 10 to 59.
5Meta-AnalyseCited 70×2022
Einfach gesagt: For moderate-to-severe acne, the most effective options for each treatment type were as follows: topical pharmacological - combined retinoid with lincosamide (clindamycin) (44·43%, 95% CrI 29·20-60·02%).
Not stated in the abstract · Br J Dermatol (2022)
179 randomised controlled trials and approximately 35,000 OBSERVATIONS (not unique participants) across 49 treatment classes, stratified by acne severity.
For MODERATE-TO-SEVERE acne, a retinoid combined with clindamycin was the most effective TOPICAL option: 44.43% (95% CrI 29.20-60.02%).
For MILD-TO-MODERATE acne the best topical was a retinoid with benzoyl peroxide (26.16%, 95% CrI 16.75-35.36%), with no clindamycin involved.
6Systematische ÜbersichtCited 31×n=18,089 · very large study2021
Einfach gesagt: The combinations of BPO with adapalene (54% vs. 35%) or with clindamycin (49% vs. 35%) were ranked more effective than BPO alone.
Not stated in the abstract · Br J Dermatol (2021)
81 papers reporting 40 trials with 18,089 participants, searched to June 2020, with confidence assessed using CINeMA.
Self-reported improvement and trial withdrawal were CO-PRIMARY outcomes, which puts a patient-reported measure on equal footing with tolerability.
Benzoyl peroxide alone was effective against vehicle (35% vs 26%). Adding clindamycin took it to 49%.
7Meta-AnalyseCited 47×n=7,309 · very large study2010
Einfach gesagt: At 10- to 12-week end points … weighted mean inflammatory lesion reduction: BPO = 43.7%, CL = 45.9%, BPO + SA = 51.8%, BPO/CL = 55.6%, placebo = 26.8%.
Seidler EM, Kimball AB · J Am Acad Dermatol (2010)
23 studies, 7,309 patients, conducted under Cochrane guidance and reported to PRISMA.
The abstract's own headline is a different drug: 5% benzoyl peroxide with salicylic acid had the greatest early reductions of any arm (55.2% inflammatory, 42.7% non-inflammatory at 2-4 weeks).
⚠️ THE TIME POINT CHANGES THE NUMBERS. At 2-4 weeks clindamycin reads lowest of the actives (inflammatory 21.5% against benzoyl peroxide's 33.4%); by 10-12 weeks the two read 45.9% against 43.7%.
8Systematische ÜbersichtCited 20×2014
Einfach gesagt: Clindamycin/BPO seemed to act more quickly than adapalene. … Adapalene/BPO and clindamycin/BPO showed comparable TOA.
Not stated in the abstract · Br J Dermatol (2014)
Systematic review of head-to-head trials in mild-to-moderate papulopustular acne. Primary outcome was time until a 25% reduction in mean inflammatory lesions.
Clindamycin with benzoyl peroxide seemed to act more quickly than adapalene, and comparably to adapalene with benzoyl peroxide.
⚠️ Against benzoyl peroxide ALONE the results were inconsistent, with only a slight indication of a shorter time to onset for the clindamycin combination.
9Meta-AnalyseCited 6×2016
Einfach gesagt: An increase in bacterial resistance to topical erythromycin and clindamycin can be confirmed, thus the use of these antibiotics is recommended in selective cases for short periods, and in combination with benzoyl peroxide for the best clinical outcome.
Not stated in the abstract · Cir Cir (2016)
13 articles reporting antibiogram results from patients with acne over a ten-year window.
Mean odds ratio 1.24, described by the authors as a slight tendency toward resistance in Propionibacterium acnes (now Cutibacterium acnes). ⚠️ The abstract gives no confidence interval for it.
⚠️ The effect is modest and the paper frames the topic as a controversy rather than a settled question. It is cited here for the direction of travel, not a precise risk.